Balfaxar is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients.
Octapharma USA today announced the U.S. Food & Drug Administration has approved cutaquig [Immune globulin, Subcutaneous (Human)-hipp, 16.5% Solution] for the treatment of pediatric patients age 2 and older with primary humoral immunodeficiency (PI). The FDA previously approved cutaquig for adults with PI.
FDA Approves Intravenous Immunoglobulin for Dermatomyositis medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Octapharma Selects Model N Revenue Cloud for Life Sciences
January 7, 2021 GMT
SAN MATEO, Calif. (BUSINESS WIRE) Jan 7, 2021
Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, today announced that specialty manufacturer Octapharma USA, Inc. has selected the Model N Revenue Management Cloud for Life Sciences, including Model N’s Provider Management and Provider Intelligence applications, as its revenue management system of record. Working diligently to combat the worldwide COVID-19 pandemic through the development of plasma derived blood product therapies, fast-growing Octapharma USA will leverage the Model N solution as part of an overall reengineering of its legacy, manually-based revenue management processes.